Skip to main content
SpringerLink
Log in

Development of a Leukæmia resistant to Cyclophosphamide (‘Cytoxan’)

  • Letter
  • Published:

From Nature

View current issue Submit your manuscript

Abstract

THE alkylating agent, N,N-bis-(β-chlorethyl)-N′, O-propylenephosphoric acid ester diamide1 (B-518, cyclophosphamide, ‘Endoxan’, ‘Cytoxan’), has been markedly effective in suppressing the growth of a variety of transplanted tumours in rats2,3 and mice3. The mechanism of activation of this agent has not been determined. It is known that the drug is not cytotoxic in vitro, but is activated in vivo 4. Nicotinamide has been reported to prevent the toxic and antitumour effects of ‘Cytoxan’5. However, the relationship of nicotinamide or diphosphopyridine nucleotide to either the activation or the action of this alkylating agent is unknown. Resistant tumours have proved valuable for the study of the mechanism of action of chemotherapeutic compounds. Sublines resistant to alkylating agents and derived from previously sensitive tumours are uncommon and have not been investigated extensively. It was thought that if a tumour resistant to ‘Cytoxan’ could be developed, it might provide a useful model for the study of the action of this alkylating agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnold, H., and Bourseaux, F., Angew. Chemie, 70, 539 (1958).

    Article  CAS  Google Scholar 

  2. Brock, N., and Wilmanns, H., Deut. med. Wchnschr., 83, 453 (1958).

    Article  CAS  Google Scholar 

  3. Lane, M., and Kelly, M. G., Proc. Amer. Assoc. Cancer Res., 3, 35 (1959).

    Google Scholar 

  4. Arnold, H., Bourseaux, F., and Brock, N., Naturwiss., 45, 64 (1958). Burchenal, J. H., Oettgen, H. F., Reppert, J. A., and Coley, V., Proc. Amer. Assoc. Cancer Res., 3, 99 (1960). Foley, G. E., Friedman, O. M., and Drolet, B. P., ibid, 3, 111 (1960). Wight, K., Burk, D., Woods, M., and Lane, M., ibid., 3, 162 (1960).

    Article  ADS  CAS  Google Scholar 

  5. Holzer, H., and Kröger, H., Klin. Wchnschr., 36, 677 (1958).

    Article  CAS  Google Scholar 

  6. Lane, M., Fed. Proc., 18, 413 (1959).

    Google Scholar 

  7. Lane, M., J. Nat. Cancer Inst., 23, 1347 (1959).

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. MONTAGUE LANE

    Present address: Department of Pharmacology (Medicine), Baylor University College of Medicine, Houston, 25, Texas

Authors and Affiliations

  1. General Medicine Branch, National Cancer Institute, Bethesda, 14, Maryland

    MONTAGUE LANE & SIDNEY T. YANCEY

Authors
  1. MONTAGUE LANE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SIDNEY T. YANCEY
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

LANE, M., YANCEY, S. Development of a Leukæmia resistant to Cyclophosphamide (‘Cytoxan’). Nature 188, 756–757 (1960). https://doi.org/10.1038/188756a0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/188756a0

  • Springer Nature Limited

This article is cited by

Search

Navigation